Evidence map›Paper›PMID 34097201›Full record

ArticleMolecular biology reports2021

Association between RAD51, XRCC2 and XRCC3 gene polymorphisms and risk of ovarian cancer: a case control and an in silico study.

G Gowtham Kumar, Solomon Franklin Durairaj Paul, Jovita Martin, M Manickavasagam, Shirley Sundersingh, Nalini Ganesan, R Ramya, G Usha Rani, Francis Andrea Mary

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

G Gowtham KumarDepartment of Human Genetics, Faculty of Biomedical Sciences, Technology and Research, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600116, Tamilnadu, India.
Solomon Franklin Durairaj PaulDepartment of Human Genetics, Faculty of Biomedical Sciences, Technology and Research, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600116, Tamilnadu, India.
Jovita MartinDepartment of Medical Oncology, Sri Ramachandra Institute of Higher Education and Research (DU), Tamilnadu, India.
M ManickavasagamDepartment of Medical Oncology, Sri Ramachandra Institute of Higher Education and Research (DU), Tamilnadu, India.
Shirley SundersinghDepartment of Oncopathology, Cancer Institute (WIA), Chennai, Tamilnadu, India.
Nalini GanesanDepartment of Biochemistry, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamilnadu, India.
R RamyaDepartment of General Surgery, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamilnadu, India.
G Usha RaniDepartment of Obstetrics and Gynecology, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamilnadu, India.
Francis Andrea MaryDepartment of Human Genetics, Faculty of Biomedical Sciences, Technology and Research, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600116, Tamilnadu, India. andreamary@sriramachandra.edu.in.ORCID http://orcid.org/0000-0003-2260-7199
Sri Ramachandra Institute of Higher Education and Research · INCancer Institute (WIA) · IN

Funding

Department of Biotechnology , Ministry of Science and Technology 6242-P43/RGCB/PMD/DBT/ANDR/2015
6 · The paper itself

Abstract

Homologous recombination (HR) is one of the important mechanisms in repairing double-strand breaks to maintain genomic integrity and DNA stability from the cytotoxic effects and mutations. Various studies have reported that single nucleotide polymorphisms (SNPs) in the HR-associated genes may have a significant association with ovarian cancer (OCa) risk but the results were inconclusive. In the present study, five polymorphisms of HR-associated genes (RAD51, XRCC2 and XRCC3) were genotyped by allelic discrimination assay in 200 OCa cases and 200 healthy individuals. The association with OCa risk was evaluated by unconditional logistic regression analyses. The results revealed that the mutant allele in both rs1801320 (CC) and rs1801321 (TT) of RAD51 gene was associated with increased risk of OCa (odds ratio [OR] 3.79, 95% confidence interval [CI] 1.21-11.78, p = 0.014 and OR 1.61, 95% CI 1.06-2.45, p = 0.025, respectively). Moreover, a significant association of TT allele (OR 4.68, 95% CI 1.27-17.15, p = 0.011) of rs3218536 of XRCC2 gene with OCa was observed. Stratified analysis results showed that patients with early menarche and stages 3 and 4 were found to be associated with rs1801321 of RAD51 gene and rs1799794 of XRCC3 gene. In silico analysis predicted that the two missense SNPs (rs3218536 and rs1799794) were found to have an impact on the protein structure, stability and function. The present study suggested that RAD51 and XRCC2 gene polymorphisms might have an impact on the OCa risk in the South Indian population. However, studies with a larger sample and on different populations are needed to support the conclusions.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overAllelesCase-Control StudiesComputer SimulationDNA-Binding ProteinsDNA RepairFemaleGenetic Predisposition to DiseaseHomologous RecombinationHumansIndiaMiddle AgedOvarian NeoplasmsDNA-Binding ProteinsRAD51 protein, humanRad51 RecombinaseX-ray repair cross complementing protein 3XRCC2 protein, humanDNA damageDNA repairDouble-strand breaksHomologous recombinationOvarian neoplasmsRAD51

Identifiers

PMID34097201
OpenAlexW3166253100

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.